Cargando…

Incidence and Risk Assessment for Atrial Fibrillation at 5 Years: Hypertensive Diabetic Cohort

(1) Background: The link between diabetes and hypertension is mutual and reciprocal, increasing the risks for the development of atrial fibrillation (AF). The main objective was to develop a prediction model for AF in a population with both diabetes and hypertension at five years of follow-up. (2) M...

Descripción completa

Detalles Bibliográficos
Autores principales: Muria-Subirats, Eulalia, Clua-Espuny, Josep Lluis, Ballesta-Ors, Juan, Lorman-Carbo, Blanca, Lechuga-Duran, Iñigo, Fernández-Saez, Jose, Pla-Farnos, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277633/
https://www.ncbi.nlm.nih.gov/pubmed/32429492
http://dx.doi.org/10.3390/ijerph17103491
_version_ 1783543163849277440
author Muria-Subirats, Eulalia
Clua-Espuny, Josep Lluis
Ballesta-Ors, Juan
Lorman-Carbo, Blanca
Lechuga-Duran, Iñigo
Fernández-Saez, Jose
Pla-Farnos, Roger
author_facet Muria-Subirats, Eulalia
Clua-Espuny, Josep Lluis
Ballesta-Ors, Juan
Lorman-Carbo, Blanca
Lechuga-Duran, Iñigo
Fernández-Saez, Jose
Pla-Farnos, Roger
author_sort Muria-Subirats, Eulalia
collection PubMed
description (1) Background: The link between diabetes and hypertension is mutual and reciprocal, increasing the risks for the development of atrial fibrillation (AF). The main objective was to develop a prediction model for AF in a population with both diabetes and hypertension at five years of follow-up. (2) Methods: A multicenter and community-based cohort study was undertaken of 8237 hypertensive diabetic patients without AF between 1 January 2103 and 31 December 2017. Multivariate Cox proportional-hazards regression models were used to identify predictors AF and to stratify risk scores by quartiles. (3) Results: AF incidence was 10.5/1000 people/years (95% confidence interval (CI) 9.5–11.5), higher in men. The independent prognostic factors identified: age (hazard ratio (HR) 1.07 95% CI 1.05–1.09, p < 0.001), weight (HR 1.03 95% CI 1.02–1.04, p < 0.001), CHA(2)DS(2)VASc score (HR 1.57 95% CI 1.16–2.13, p = 0.003) and female gender (HR 0.55 95% CI 0.37–0.82, p = 0.004). Q4 (highest-risk group for AF) had the highest AF incidence, stroke and mortality, and the smallest number needed to screen to detect one case of AF. (4) Conclusions: Risk-based screening for AF should be used in high cardiovascular risk patients as the hypertensive diabetics, for treatment of modifiable cardiovascular risk, and monitoring AF detection.
format Online
Article
Text
id pubmed-7277633
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72776332020-06-12 Incidence and Risk Assessment for Atrial Fibrillation at 5 Years: Hypertensive Diabetic Cohort Muria-Subirats, Eulalia Clua-Espuny, Josep Lluis Ballesta-Ors, Juan Lorman-Carbo, Blanca Lechuga-Duran, Iñigo Fernández-Saez, Jose Pla-Farnos, Roger Int J Environ Res Public Health Article (1) Background: The link between diabetes and hypertension is mutual and reciprocal, increasing the risks for the development of atrial fibrillation (AF). The main objective was to develop a prediction model for AF in a population with both diabetes and hypertension at five years of follow-up. (2) Methods: A multicenter and community-based cohort study was undertaken of 8237 hypertensive diabetic patients without AF between 1 January 2103 and 31 December 2017. Multivariate Cox proportional-hazards regression models were used to identify predictors AF and to stratify risk scores by quartiles. (3) Results: AF incidence was 10.5/1000 people/years (95% confidence interval (CI) 9.5–11.5), higher in men. The independent prognostic factors identified: age (hazard ratio (HR) 1.07 95% CI 1.05–1.09, p < 0.001), weight (HR 1.03 95% CI 1.02–1.04, p < 0.001), CHA(2)DS(2)VASc score (HR 1.57 95% CI 1.16–2.13, p = 0.003) and female gender (HR 0.55 95% CI 0.37–0.82, p = 0.004). Q4 (highest-risk group for AF) had the highest AF incidence, stroke and mortality, and the smallest number needed to screen to detect one case of AF. (4) Conclusions: Risk-based screening for AF should be used in high cardiovascular risk patients as the hypertensive diabetics, for treatment of modifiable cardiovascular risk, and monitoring AF detection. MDPI 2020-05-16 2020-05 /pmc/articles/PMC7277633/ /pubmed/32429492 http://dx.doi.org/10.3390/ijerph17103491 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Muria-Subirats, Eulalia
Clua-Espuny, Josep Lluis
Ballesta-Ors, Juan
Lorman-Carbo, Blanca
Lechuga-Duran, Iñigo
Fernández-Saez, Jose
Pla-Farnos, Roger
Incidence and Risk Assessment for Atrial Fibrillation at 5 Years: Hypertensive Diabetic Cohort
title Incidence and Risk Assessment for Atrial Fibrillation at 5 Years: Hypertensive Diabetic Cohort
title_full Incidence and Risk Assessment for Atrial Fibrillation at 5 Years: Hypertensive Diabetic Cohort
title_fullStr Incidence and Risk Assessment for Atrial Fibrillation at 5 Years: Hypertensive Diabetic Cohort
title_full_unstemmed Incidence and Risk Assessment for Atrial Fibrillation at 5 Years: Hypertensive Diabetic Cohort
title_short Incidence and Risk Assessment for Atrial Fibrillation at 5 Years: Hypertensive Diabetic Cohort
title_sort incidence and risk assessment for atrial fibrillation at 5 years: hypertensive diabetic cohort
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277633/
https://www.ncbi.nlm.nih.gov/pubmed/32429492
http://dx.doi.org/10.3390/ijerph17103491
work_keys_str_mv AT muriasubiratseulalia incidenceandriskassessmentforatrialfibrillationat5yearshypertensivediabeticcohort
AT cluaespunyjoseplluis incidenceandriskassessmentforatrialfibrillationat5yearshypertensivediabeticcohort
AT ballestaorsjuan incidenceandriskassessmentforatrialfibrillationat5yearshypertensivediabeticcohort
AT lormancarboblanca incidenceandriskassessmentforatrialfibrillationat5yearshypertensivediabeticcohort
AT lechugaduraninigo incidenceandriskassessmentforatrialfibrillationat5yearshypertensivediabeticcohort
AT fernandezsaezjose incidenceandriskassessmentforatrialfibrillationat5yearshypertensivediabeticcohort
AT plafarnosroger incidenceandriskassessmentforatrialfibrillationat5yearshypertensivediabeticcohort
AT incidenceandriskassessmentforatrialfibrillationat5yearshypertensivediabeticcohort